• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

47.27 -1.46 (-3.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
June 01, 2026
From Veracyte
Via Business Wire
News headline image
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
May 30, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
May 29, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
May 22, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
May 21, 2026
From Veracyte
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
May 19, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
May 15, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
May 13, 2026
Issued on behalf of VentriPoint Diagnostics Ltd. 
From USA News Group
Via GlobeNewswire
News headline image
Veracyte Announces First Quarter 2026 Financial Results
May 05, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
April 28, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
April 14, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Names Kevin Haas as Chief Development and Technology Officer
March 16, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
February 25, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
February 24, 2026
From Veracyte
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
February 19, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
February 04, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
January 11, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 29, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
November 06, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Third Quarter 2025 Financial Results
November 04, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
October 15, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
November 03, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
September 28, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
September 24, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
September 09, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 29, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
August 27, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
August 26, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Second Quarter 2025 Financial Results
August 06, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
July 17, 2025
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap